Delivery time2024-10-23 11:25
Summary Change font size Share
“Possibility of side effects when used for cosmetic purposes… Monitoring of illegal distribution and side effects is necessary.”
Wegobi“/>
Obesity treatment Wegobi
(Seoul = Yonhap News) Reporter Seo Dae-yeon [연합뉴스 자료사진]
(Seoul = Yonhap News) Reporter Kim Jan-di = As concerns grew about misuse of the obesity treatment drug ‘Wegobi’ due to illegal online distribution after its launch in Korea, the Korean Society of Obesity called for active management by health authorities to ensure that it can be used only within a specified range. issued a statement.
The Korean Society of Obesity said on the 23rd, “We welcome the launch of Wigobi, known as one of the effective drugs at a time when obesity has become a serious social problem, but as soon as it was released, concerns about misuse and abuse have become a reality, with distribution and trading for cosmetic purposes occurring.” He said.
The society pointed out, “Wegobi is a drug made for the treatment of obese patients, and is a prescription drug that requires a doctor’s prescription,” adding, “Those eligible for treatment are clearly determined based on body mass index (BMI).”
At the same time, he said, “The Ministry of Health and Welfare and the Ministry of Food and Drug Safety should make efforts to reduce the misuse and abuse of incretin-based drugs such as Wigobi and ensure that the public can safely prescribe and use them.” “We urge only obese patients to use it,” he said.
In particular, he mentioned that side effects may occur if used indiscriminately and repeatedly emphasized that it should be used under the guidance and monitoring of a doctor.
The society said, “Although Wigobi has an excellent weight loss effect, it can also cause various side effects such as nausea, vomiting, constipation, diarrhea, abdominal distension, aspiration pneumonia, and pancreatitis,” and added, “It is effective when used for cosmetic purposes rather than obesity treatment.” “You may experience side effects,” he warned.
He added, “Previously, obesity treatment drugs released in Korea have been used for cosmetic purposes or distributed illegally online,” adding, “To reduce misuse, we must thoroughly crack down on illegal distribution and actively monitor side effects.”
Wigobi is an obesity treatment drug that acts on the glucagon-like peptide-1 (GLP-1) receptor. It has the effect of reducing weight by slowing down gastrointestinal motility and acting on the central nervous system to suppress appetite.
It was officially released in Korea on the 15th of this month. It can be prescribed for obese patients with a BMI of 30 or more, or overweight patients with a BMI of 27 to 30 and accompanied by high blood pressure and dyslipidemia.
jandi@yna.co.kr
Report via KakaoTalk okjebo
Unauthorized reproduction/redistribution, AI learning and use prohibited>
2024/10/23 11:25 Sent
